Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Loss of Multimerin-2 and EMILIN-2 Expression in Gastric Cancer Associate with Altered Angiogenesis.

Andreuzzi E, Capuano A, Pellicani R, Poletto E, Doliana R, Maiero S, Fornasarig M, Magris R, Colombatti A, Cannizzaro R, Spessotto P, Mongiat M.

Int J Mol Sci. 2018 Dec 11;19(12). pii: E3983. doi: 10.3390/ijms19123983.

2.

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D.

Haematologica. 2019 Mar;104(3):564-575. doi: 10.3324/haematol.2018.196725. Epub 2018 Oct 11.

3.

Endorepellin remodels the endothelial transcriptome toward a pro-autophagic and pro-mitophagic gene signature.

Neill T, Andreuzzi E, Wang ZX, Peiper SC, Mongiat M, Iozzo RV.

J Biol Chem. 2018 Aug 3;293(31):12137-12148. doi: 10.1074/jbc.RA118.002934. Epub 2018 Jun 19.

4.

Fibroblast growth factor 23 and renal function among young and healthy individuals.

Bernasconi R, Aeschbacher S, Blum S, Mongiat M, Girod M, Todd J, Estis J, Nolan N, Renz H, Risch L, Conen D, Risch M.

Clin Chem Lab Med. 2018 Aug 28;56(9):1483-1489. doi: 10.1515/cclm-2017-1183.

PMID:
29708879
5.

The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.

Paulitti A, Andreuzzi E, Bizzotto D, Pellicani R, Tarticchio G, Marastoni S, Pastrello C, Jurisica I, Ligresti G, Bucciotti F, Doliana R, Colladel R, Braghetta P, Poletto E, Di Silvestre A, Bressan G, Colombatti A, Bonaldo P, Mongiat M.

Oncogene. 2018 Jun;37(25):3399-3414. doi: 10.1038/s41388-017-0107-x. Epub 2018 Feb 27.

PMID:
29483644
6.

Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.

Galvagni F, Nardi F, Spiga O, Trezza A, Tarticchio G, Pellicani R, Andreuzzi E, Caldi E, Toti P, Tosi GM, Santucci A, Iozzo RV, Mongiat M, Orlandini M.

Matrix Biol. 2017 Dec;64:112-127. doi: 10.1016/j.matbio.2017.08.003. Epub 2017 Sep 11.

PMID:
28912033
7.

Probe-based confocal laser endomicroscopy for in vivo evaluation of the tumor vasculature in gastric and rectal carcinomas.

Spessotto P, Fornasarig M, Pivetta E, Maiero S, Magris R, Mongiat M, Canzonieri V, De Paoli P, De Paoli A, Buonadonna A, Serraino D, Panato C, Belluco C, Cannizzaro R.

Sci Rep. 2017 Aug 29;7(1):9819. doi: 10.1038/s41598-017-10963-1.

8.

The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis.

Andreuzzi E, Colladel R, Pellicani R, Tarticchio G, Cannizzaro R, Spessotto P, Bussolati B, Brossa A, De Paoli P, Canzonieri V, Iozzo RV, Colombatti A, Mongiat M.

Matrix Biol. 2017 Dec;64:40-53. doi: 10.1016/j.matbio.2017.04.002. Epub 2017 Apr 21.

PMID:
28435016
9.

Extracellular Matrix, a Hard Player in Angiogenesis.

Mongiat M, Andreuzzi E, Tarticchio G, Paulitti A.

Int J Mol Sci. 2016 Nov 1;17(11). pii: E1822. Review.

10.

MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth.

Colladel R, Pellicani R, Andreuzzi E, Paulitti A, Tarticchio G, Todaro F, Colombatti A, Mongiat M.

Oncotarget. 2016 Jan 12;7(2):2022-37. doi: 10.18632/oncotarget.6515.

11.

Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D.

Blood. 2015 Sep 10;126(11):1394-7. doi: 10.1182/blood-2015-07-660365. Epub 2015 Jul 30. No abstract available.

12.

Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Clin Cancer Res. 2014 Nov 1;20(21):5496-506. doi: 10.1158/1078-0432.CCR-14-0713. Epub 2014 Sep 17.

13.

Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.

Celegato M, Fregona D, Mongiat M, Ronconi L, Borghese C, Canzonieri V, Casagrande N, Nardon C, Colombatti A, Aldinucci D.

Future Med Chem. 2014 Jul;6(11):1249-63. doi: 10.4155/fmc.14.81.

PMID:
25162999
14.

EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration.

Marastoni S, Andreuzzi E, Paulitti A, Colladel R, Pellicani R, Todaro F, Schiavinato A, Bonaldo P, Colombatti A, Mongiat M.

J Pathol. 2014 Mar;232(4):391-404. doi: 10.1002/path.4316.

PMID:
24374807
15.

Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.

Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Gynecol Oncol. 2013 Dec;131(3):744-52. doi: 10.1016/j.ygyno.2013.08.041. Epub 2013 Sep 10.

PMID:
24029417
16.
17.

Endomicroscopy and cancer: a new approach to the visualization of neoangiogenesis.

Cannizzaro R, Mongiat M, Canzonieri V, Fornasarig M, Maiero S, De Re V, Todaro F, De Paoli P, Spessotto P.

Gastroenterol Res Pract. 2012;2012:537170. doi: 10.1155/2012/537170. Epub 2012 Jan 12.

18.

MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.

Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, Ligresti G, Colombatti A, Mongiat M.

Oncogene. 2012 Jun 28;31(26):3136-47. doi: 10.1038/onc.2011.487. Epub 2011 Oct 24.

PMID:
22020326
19.

The value of 64-detector row computed tomography for the exclusion of pulmonary embolism.

Pesavento R, de Conti G, Minotto I, Filippi L, Mongiat M, de Faveri D, Maurizi F, Dalla Valle F, Piovella C, Pagnan A, Prandoni P; TACEP study.

Thromb Haemost. 2011 May;105(5):901-7. doi: 10.1160/TH10-10-0638. Epub 2011 Feb 8.

PMID:
21301781
20.

The EMILIN/Multimerin family.

Colombatti A, Spessotto P, Doliana R, Mongiat M, Bressan GM, Esposito G.

Front Immunol. 2012 Jan 6;2:93. doi: 10.3389/fimmu.2011.00093. eCollection 2011.

21.

The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.

Mongiat M, Marastoni S, Ligresti G, Lorenzon E, Schiappacassi M, Perris R, Frustaci S, Colombatti A.

Neoplasia. 2010 Apr;12(4):294-304.

22.

Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts.

Cattaruzza L, Fregona D, Mongiat M, Ronconi L, Fassina A, Colombatti A, Aldinucci D.

Int J Cancer. 2011 Jan 1;128(1):206-15. doi: 10.1002/ijc.25311.

23.

Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow.

Mazzucato M, Cozzi MR, Battiston M, Jandrot-Perrus M, Mongiat M, Marchese P, Kunicki TJ, Ruggeri ZM, De Marco L.

Blood. 2009 Sep 24;114(13):2793-801. doi: 10.1182/blood-2008-12-193490. Epub 2009 Jul 21.

24.

Extracellular matrix: a matter of life and death.

Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M.

Connect Tissue Res. 2008;49(3):203-6. doi: 10.1080/03008200802143190. Review.

PMID:
18661343
25.

EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro.

Doliana R, Veljkovic V, Prljic J, Veljkovic N, De Lorenzo E, Mongiat M, Ligresti G, Marastoni S, Colombatti A.

Matrix Biol. 2008 Mar;27(2):96-106. Epub 2007 Oct 10.

PMID:
17988845
26.

Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2.

Mongiat M, Ligresti G, Marastoni S, Lorenzon E, Doliana R, Colombatti A.

Mol Cell Biol. 2007 Oct;27(20):7176-87. Epub 2007 Aug 13.

27.

A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth.

Gonzalez EM, Mongiat M, Slater SJ, Baffa R, Iozzo RV.

J Biol Chem. 2003 Oct 3;278(40):38113-6. Epub 2003 Aug 4.

28.

Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis.

Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown AM, Iozzo RV.

J Biol Chem. 2003 May 9;278(19):17491-9. Epub 2003 Feb 25.

29.

Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan.

Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV.

J Biol Chem. 2003 Feb 7;278(6):4238-49. Epub 2002 Nov 14.

30.

Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.

Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E, Cozzolino F, Torcia MG.

Prostate. 2002 Dec 1;53(4):310-21.

PMID:
12430142
31.

Fibroblast growth factor-binding protein is a novel partner for perlecan protein core.

Mongiat M, Otto J, Oldershaw R, Ferrer F, Sato JD, Iozzo RV.

J Biol Chem. 2001 Mar 30;276(13):10263-71. Epub 2001 Jan 8.

32.

The EMILIN protein family.

Colombatti A, Doliana R, Bot S, Canton A, Mongiat M, Mungiguerra G, Paron-Cilli S, Spessotto P.

Matrix Biol. 2000 Aug;19(4):289-301. Review.

PMID:
10963989
33.

Self-assembly and supramolecular organization of EMILIN.

Mongiat M, Mungiguerra G, Bot S, Mucignat MT, Giacomello E, Doliana R, Colombatti A.

J Biol Chem. 2000 Aug 18;275(33):25471-80.

34.

The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7.

Mongiat M, Taylor K, Otto J, Aho S, Uitto J, Whitelock JM, Iozzo RV.

J Biol Chem. 2000 Mar 10;275(10):7095-100.

35.

Structure, chromosomal localization, and promoter analysis of the human elastin microfibril interfase located proteIN (EMILIN) gene.

Doliana R, Canton A, Bucciotti F, Mongiat M, Bonaldo P, Colombatti A.

J Biol Chem. 2000 Jan 14;275(2):785-92.

36.

EMILIN, a component of the elastic fiber and a new member of the C1q/tumor necrosis factor superfamily of proteins.

Doliana R, Mongiat M, Bucciotti F, Giacomello E, Deutzmann R, Volpin D, Bressan GM, Colombatti A.

J Biol Chem. 1999 Jun 11;274(24):16773-81.

37.

The human alpha3b is a 'full-sized' laminin chain variant with a more widespread tissue expression than the truncated alpha3a.

Doliana R, Bellina I, Bucciotti F, Mongiat M, Perris R, Colombatti A.

FEBS Lett. 1997 Nov 3;417(1):65-70.

Supplemental Content

Loading ...
Support Center